Further longitudinal studies with larger numbers of patients are required to determine the role of the BAFF/APRIL system and to determine whether BAFF and APRIL might serve as therapeutic targets in IgG4-RD. This evidence concerns the gene TNFSF13 and immunoglobulin G4-related sclerosing disease.